Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527669 | 1.00 | ACP3 (0.42) | ACP3CNR2SMN1; SMN2HPGDP2RX7 | |
| SCHEMBL2346776 | 0.85 | ACP3 (0.46) | ACP3CNR2SMN1; SMN2HPGDMAOB | |
| SCHEMBL2351342 | 0.85 | ACP3 (0.46) | ACP3CNR2SMN1; SMN2HPGDMAOB | |
| SCHEMBL2703078 | 0.85 | ACP3 (0.46) | ACP3CNR2SMN1; SMN2HPGDMAOB | |
| SCHEMBL8887298 | 0.84 | ACP3 (0.42) | ACP3CNR2SMN1; SMN2HPGDMAOB | |
| Hydrochloric Acid SCHEMBL5595953 | 0.84 | ACP3 (0.45) | ACP3CNR2SMN1; SMN2HPGDMAOB | |
| SCHEMBL11556739 | 0.82 | FABP4 (0.38) | SMN1; SMN2LMNAGAATSHRMAPT | |
| SCHEMBL28969367 | 0.78 | ACP3 (0.45) | ACP3CNR2SMN1; SMN2P2RX7LMNA | |
| SCHEMBL5918008 | 0.76 | FABP4 (0.44) | ACP3LMNAKMT2A | |
| SCHEMBL28327500 | 0.76 | ACP3 (0.46) | ACP3CNR2P2RX7MAOBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407403-B2 | Preparation method of cobimetinib | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2019-09-10 | — | — | US | disclosed |
| US-20180273506-A1 | Preparation Method of Cobimetinib | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2018-09-27 | — | — | US | disclosed |
| WO-2013103841-A1 | METHODS FOR QUANTITATIVE CHIRAL DETERMINATION OF THE d- AND l- ENANTIOMERS OF AMPHETAMINE AND METHAMPHETAMINE | CLINICAL REFERENCE LABORATORY, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| US-20130177994-A1 | METHODS FOR QUANTITATIVE CHIRAL DETERMINATION OF THE d- AND l- ENANTIOMERS OF AMPHETAMINE AND METHAMPHETAMINE | CLINICAL REFERENCE LABORATORY, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2012015944-A2 | NOVEL TETRAHYDRONAPHALENE ANTAGONISTS TO THE THROMBOXANE A2 (TP) RECEPTOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-02-02 | — | — | WO | disclosed |
| EP-1615937-A2 | ANALOGS OF LYSOPHOSPHATIDIC ACID AND METHODS OF MAKING AND USING THEREOF | University of Utah Research Foundation (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004092188-A2 | ANALOGS OF LYSOPHOSPHATIDIC ACID AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2004-10-28 | — | — | WO | disclosed |
| EP-1368325-A1 | NEW ASYMMETRIC PROCESS FOR THE PREPARATION OF DIARYLMETHYLPIPERAZINES DERIVATIVES AND NOVEL ASYMMETRIC DIARYLMETYLAMINES AS INTERMEDIATES | AstraZeneca AB (SE) | 2003-12-10 | — | — | EP | disclosed |
| US-6562850-B1 | In which numbering of the atoms is started with the sulfur atom of the isothiazole. Two of the rings (rings A and C) are aromatic, and the third is a heterocyclic ring (ring B), a cyclic sulfonamide. Of particular importance are enantiomorph | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION | 2003-05-13 | — | — | US | disclosed |
| WO-2002070492-A1 | NEW ASYMMETRIC PROCESS FOR THE PREPARATION OF DIARYLMETHYLPIPERAZINES DERIVATIVES AND NOVEL ASYMMETRIC DIARYLMETYLAMINES AS INTERMEDIATES | ASTRAZENECA AB (SE) | 2002-09-12 | — | — | WO | disclosed |
| EP-0766679-A4 | BIOACTIVE ACETOGENINS AND DERIVATIVES | PURDUE RESEARCH FOUNDATION (US) | 2000-11-02 | — | — | EP | disclosed |
| EP-0767772-B1 | NOVEL CHIRAL CYCLOHEXYL COMPOUNDS | SECR DEFENCE (GB) | 2000-08-30 | — | — | EP | disclosed |
| WO-2000004004-A1 | METHODS OF SYNTHESIZING SULTAMS AND ANTI-VIRAL COMPOSITIONS | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2000-01-27 | — | — | WO | disclosed |
| US-5853613-A | Chiral cyclohexyl compounds | SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1998-12-29 | — | — | US | disclosed |
| EP-0766679-A1 | BIOACTIVE ACETOGENINS AND DERIVATIVES | PURDUE RESEARCH FOUNDATION (US) | 1997-04-09 | — | — | EP | disclosed |
| EP-0695294-A1 | MICHELLAMINES USEFUL AS ANTIVIRAL AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407403-B2 | Preparation method of cobimetinib | TET2, ABL1, CBLC | ACP3 4171/4885CNR2 2883/4885SMN1; SMN2 3451/4885 |
| US-20180273506-A1 | Preparation Method of Cobimetinib | TET2, ABL1, CBLC | ACP3 4171/4885CNR2 2883/4885SMN1; SMN2 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.